NF2 and neoplasm: As previously discussed in the Children’s Tumor Foundation forum, Dr. M. Wootton, CEO of NF2 Therapeutics, mentioned that they have a monkey model of NF2 gene replacement, and based on this, he went on to state that the first human clinical trials for this NF2 transgene may start in 2022 or 2023.